The National Institute for Health and Care Excellence (NICE) is now backing routine NHS commissioning of Teva’s Cinqaero to treat a severe form of asthma after having initially been minded to block the drug’s use.
GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory disease of the nasal passage linings or sinuses causing soft tissue growth in the upper nasal cavity.
GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.